Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Contact Supplier

Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 220619-73-8, Agn194204, Irx4204, Vtp-194204, Agn-194204, Nrx194204

Molecular Formula

C₂₄H₃₂O₂

Molecular Weight

352.5 g/mol

InChI Key

BOOOLEGQBVUTKC-NVQSDHBMSA-N

FDA UNII

877M97Z38Y

Rexinoid NRX 194204 is an orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic and anti-inflammatory activities. Rexinoid NRX 194204 selectively binds to and activates RXRs. Because RXRs can form heterodimers with several nuclear receptors (NRs), RXR activation by this agent may result in a broad range of gene expression depending on the effector DNA response elements activated. Rexinoid NRX 194204 may inhibit the tumor-necrosis factor (TNF)-mediated release of nitric oxide (NO) and interleukin 6 (IL6) and may inhibit tumor cell proliferation. This agent appears to be less toxic than RAR-selective ligands.

1 2D Structure

IRX4204

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2E,4E)-3-methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid

2.1.2 InChI

InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1

2.1.3 InChI Key

BOOOLEGQBVUTKC-NVQSDHBMSA-N

2.1.4 Canonical SMILES

CC(=CC(=O)O)C=CC1CC1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C

2.1.5 Isomeric SMILES

C/C(=C\C(=O)O)/C=C/[C@@H]1C[C@]1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C

2.2 Other Identifiers

2.2.1 UNII

877M97Z38Y

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Agn 194204

2. Agn-194204

3. Agn194204

4. Nrx 194204

5. Nrx-194204

6. Nrx194204

2.3.2 Depositor-Supplied Synonyms

1. 220619-73-8

2. Agn194204

3. Irx4204

4. Vtp-194204

5. Agn-194204

6. Nrx194204

7. Nrx-194204

8. Chembl75133

9. Iso Irx-a

10. 877m97z38y

11. Vtp 194204

12. (+)-vtp-194204

13. (2e,4e)-3-methyl-5-((1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic Acid

14. Agn 194204

15. (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic Acid

16. Nrx 194204

17. Schembl3437269

18. Unii-877m97z38y

19. 3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic Acid

20. Agn 4204

21. Irx-4204

22. Nrx 4204

23. Bdbm50101445

24. Akos040741057

25. Db11806

26. Da-70643

27. Hy-13717

28. Ms-25475

29. Pd119160

30. Kb-145960

31. Cs-0007745

32. Ns00068655

33. E98723

34. Irx4204;nrx194204;vtp 194204

35. Q27269803

36. (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic Acid

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₃₂O₂
Molecular Weight	352.5 g/mol
XLogP3	7.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	37.3
Heavy Atom Count	26
Formal Charge	0
Complexity	624
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	2
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find IRX4204 manufacturers, exporters & distributors on PharmaCompass

IRX4204

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 1,231

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?